Deepa Subramaniam
Washington, DCNPI 1588864441
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $89,505 of the $113,934 with a category attached, or 78.6%. AstraZeneca accounts for 79.0% of it on its own, with 4 other manufacturers making up the rest.
Across 79 payments — averaging $1442.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$90K
- Genentech USA, Inc.$23K
- Takeda Pharmaceuticals U.S.A., Inc.$900
- E.r. Squibb & Sons, L.L.C.$60
- AbbVie$35
Across 30 payments — averaging $14,273 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kadmon Corporation LLC$255K
- Incyte Corporation$81K
- Pfizer$37K
- Genentech, Inc.$34K
- Novocure Inc.$11K
- Eli Lilly$8K
- plus $2K from 1 others
What the payments were for
- Consulting fees$11,33810%
- Speaking & faculty fees$89,50579%
- Travel & lodging$11,57710%
- Food & beverage$1,5141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $90,061 |
| Genentech USA, Inc. | 21 | $22,878 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $900 |
| E.r. Squibb & Sons, L.L.C. | 1 | $60 |
| AbbVie | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.